Review

Unidade de Endocrinologia do Desenvolvimento e Laboratório de Hormônios e Genética Molecular LIM/42, Disciplina de Endocrinologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil

Search for more papers by this author

Berenice Bilharinho Mendonca

† Author for correspondence

Search for more papers by this author

Email the corresponding author at beremen@usp.br

Published Online:2 Nov 2010https://doi.org/10.2217/phe.10.50

View article

Abstract

Male hypogonadism results from inadequate testicular function manifested by the impairment of both testosterone secretion and spermatogenesis. Hypogonadism has several etiologies. Hypogonadotropic hypogonadism (HH) results from hypothalamic–pituitary disorders leading to a complete or partial deficiency in gonadotropin-releasing hormone (GnRH) secretion from hypothalamic neurons, or gonadotropin secretion from anterior pituitary, or defects in GnRH receptor at the pituitary. All situations result in low or normal serum gonadotropin levels and low serum testosterone levels. Congenital HH can occur isolated (idiopathic HH) or in association with olfactory dysfunction (Kallmann’s syndrome). Gonadotropin deficiency can also occur with other pituitary hormone deficiencies. Most of the congenital isolated HH are still idiopathic. However, defects in more than ten genetic loci with multiple modes of inheritance, accounting for monogenic and occasionally oligogenic presentations were found in approximately 30% of cases. Acquired HH results from a hypothalamic–pituitary structural lesion as well as from tumors, trauma, autoimmunity or radiation. Hypergonadotropic hypogonadism is characterized by elevated serum gonadotropin levels due to testicular disorders, chromosomal abnormalities (Klinefelter syndrome), genetic syndromes as well as acquired conditions (autoimmunity, chemotherapy or radiation therapy). The main clinical feature of a male infant with hypogonadism is micropenis associated with or without cryptorchidism. The diagnosis of HH at childhood is difficult and usually postponed until adult age. At pubertal age, the differential diagnosis between the constitutional delay of growth and puberty, and HH is tricky and no hormonal test can consistently distinguish between these two disorders with 100% sensitivity and specificity; therefore, clinical follow-up is essential. Optimal management of male hypogonadism depends of the underlying etiology. Genetic tests are now available to detect genetic mutations in candidate genes essential for hypothalamic–pituitary axis function. Infants with micropenis require testosterone or dihydrotestosterone therapy to increase penile length. The first-line therapy for cryptorchidism is orchiopexy. Puberty should be induced with a low dose of testosterone and fertility could be achieved with chorionic gonadotropin hormone, recombinant luteinizing hormone and follicle stimulating hormone preparations or pulsatile GnRH injection. A small subset of HH patients may have a reversible phenotype enabling the withdrawal of medication in up to 10% of cases.

Keywords:

Bibliography

1 Layman LC: Hypogonadotropic hypogonadism. Endocrinol. Metab. Clin. N. Am.36, 283–296 (2007).
Medline CASGoogle Scholar
2 Bianco SD, Kaiser U: The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism. Nat. Rev. Endocrinol.5(10),569–576 (2009).
Medline CASGoogle Scholar
3 Viswanathan V, Eugster EA: Etiology and treatment of hypogonadism in adolescents. Endocrinol. Metab. Clin. N. Am.38,719–738 (2009).
Medline CASGoogle Scholar
4 Raivio T, Falardeau J, Dwyer A et al.: Reversal of idiopathic hypogonadotropic hypogonadism. N. Engl. J. Med.357,863–873 (2007).
Medline CASGoogle Scholar
5 Grumbach MM: Commentary: A window of opportunity: the diagnosis of gonadotropin deficiency in the male infant. J. Clin. Endocrinol. Metab.90,3122–3127 (2005).
Medline CASGoogle Scholar
6 Wierman ME, Pawlowski JE, Allen MP, Xu M, Linseman DA, Nielsen-Preiss S: Molecular mechanisms of gonadotropin-releasing hormone neuronal migration. Trends Endocrinol. Metab.15(3),96–102 (2004).
Medline CASGoogle Scholar
7 Grinspon RP, Rey RA: Anti-Müllerian hormone and sertoli cell function in paediatric male hypogonadism. Horm. Res. Paediatr.73(2),81–92 (2010).
Medline CASGoogle Scholar
8 Crofton PM, Evans AEM, Groome NP, Taylor MRH, Holland CV, Kelnart CJH: Inhibin B in boys from birth to adulthood: relationship with age, pubertal stage, FSH and testosterone. Clin. Endocrinol.56,215–221 (2002).
Medline CASGoogle Scholar
9 Sharpe RM, McKinnell C, Kivlin C, Fisher JS: Proliferation and functional maturation of Sertoli cells, and their relevance to disorders of testis function in adulthood. Reproduction125,769–784 (2003).
Medline CASGoogle Scholar
10 MacLaughlin, DT, Donahoe PK: Sex determination and differentiation. N. Engl. J. Med.350,367–378 (2004).
Medline CASGoogle Scholar
11 Tsang S: When size matters: a clinical review of pathological micropenis. J. Pediatr. Health Care24(4),231–240 (2010).
MedlineGoogle Scholar
12 Hughes IA, Acerini CL: Factors controlling testis descent. Eur. J. Endocrinol.159(Suppl. 1),S75–S82 (2008).
Medline CASGoogle Scholar
13 Mendonca BB, Inacio M, Arnhold IJ et al.: Male pseudohermaphroditism due to 17 β-hydroxysteroid dehydrogenase 3 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore)79(5),299–309 (2000)
Medline CASGoogle Scholar
14 Latronico AC: The neurokinin B pathway in human reproduction. Nature Genetics41,269–270 (2009).
Medline CASGoogle Scholar
15 Trarbach EB, Silveira LG, Latronico AC: Genetic insights into human isolated gonadotropin deficiency. Pituitary10(4),381–391 (2007).
Medline CASGoogle Scholar
16 Mehta A, Dattani MT: Developmental disorders of the hypothalamus and pituitary gland associated with congenital hypopituitarism. Best Pract. Res. Clin. Endocrinol. Metab.22(1),191–206 (2008).
Medline CASGoogle Scholar
17 Zentner GE, Layman WS, Martin DM, Scacheri PC: Molecular and phenotypic aspects of CHD7 mutation in CHARGE syndrome. Am. J. Med. Genet. A.22,152(3), 674–686 (2010).
Google Scholar
18 Jongmans MCJ, van Ravenswaaij-Arts CMA, Pitteloud N et al.: CHD7 mutations in patients initially diagnosed with Kallmann syndrome – the clinical overlap with CHARGE syndrome. Clin. Genet.75,65–71(2009).
Medline CASGoogle Scholar
19 Ribeiro RS, Vieira TC, Abucham J: Reversible Kallmann syndrome: report of the first case with a KAL1 mutation and literature review. Eur. J. Endocrinol.156(3),285–290 (2007).
Medline CASGoogle Scholar
20 Sinisi AA, Asci R, Bellastella G et al.: Homozygous mutation in the prokineticin-receptor2 gene (Val274Asp) presenting as reversible Kallmann syndrome and persistent oligozoospermia: case report. Hum. Reprod.23(10),2380–2384 (2008).
Medline CASGoogle Scholar
21 Pitteloud N, Meysing A, Quinton R et al.: Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. Mol. Cell. Endocrinol.25,254–255:60–69 (2006).
Google Scholar
22 Gianetti E, Tusset C, Noel SD et al.: TAC3/TACR3 mutations reveal preferential activation of GnRH release 1 by neurokinin B2 in neonatal life followed by reversal in adulthood. J. Clin. Endocrinol. Metab.95(6),2857–2867 (2010).
Medline CASGoogle Scholar
23 Semple RK, Topaloglu A: The recent genetics of hypogonadotrophic hypogonadism – novel insights and new questions. Clin. Endocrinol. (Oxf.).72(4),427–435 (2010).
Medline CASGoogle Scholar
24 Bittel DC, Butler MG: Prader–Willi syndrome: clinical genetics, cytogenetics and molecular biology. Expert Rev. Mol. Med.25,1–20 (2005).
Google Scholar
25 de Smith AJ, Purmann C, Walters RG et al.: A deletion of the HBII-85 class of small nucleolar RNAs (snoRNAs) is associated with hyperphagia, obesity and hypogonadism. Hum. Mol. Genet.18(17),3257–3265 (2009).
Medline CASGoogle Scholar
26 Merchant TE, Williams T, Smith JM et al.: Preirradiation endocrinopathies in pediatric brain tumor patients determined by dynamic tests of endocrine function. Int. J. Radiat. Oncol. Biol. Phys.54(1),45–50 (2002).
MedlineGoogle Scholar
27 Gonc EN, Yordam N, Ozon A: Endocrine outcome of different treatment options in children with craniopharyngioma: a retrospective analysis of 66 cases. Pediatr. Neurosurg.40,112–119 (2004).
MedlineGoogle Scholar
28 Knoepfelmacher M, Gomes MC, Melo ME, Mendonca BB: Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma. Pituitary7(2),83–87 (2004).
MedlineGoogle Scholar
29 Acerini CL, Tasker RC: Endocrine sequelae of traumatic brain injury in childhood. Horm. Res.68(5),14–17 (2007).
MedlineGoogle Scholar
30 Schneider HJ, Corneli G, Kreitschman-Andermahr I et al.: Traumatic brain injury and hypopituitarism in children and adolescents: is the problem under-estimated? Pediatr. Endocrinol. Rev.4(3),205–209 (2007).
MedlineGoogle Scholar
31 Mouritsen A, Aksglaede L, Sørensen K et al.: Hypothesis: exposure to endocrine-disrupting chemicals may interfere with timing of puberty. Int. J. Androl.33(2),346–359 (2010).
Medline CASGoogle Scholar
32 Soneda S, Fukami M, Fujimoto M, Hasegawa T, Koitabashi Y, Ogata T: Association of micropenis with Pro185Ala polymorphism of the gene for aryl hydrocarbon receptor repressor involved in dioxin signaling. Endocr. J.52(1),83–88 (2005).
Medline CASGoogle Scholar
33 Wikström AM, Dunkel L: Testicular function in Klinefelter syndrome. Horm. Res.69(6),317–326 (2008).
Medline CASGoogle Scholar
34 Bastida MG, Rey RA, Bergadá I et al.: Establishment of testicular endocrine function impairment during childhood and puberty in boys with Klinefelter syndrome. Clin. Endocrinol.(Oxf.)67(6),863–870 (2007).
Medline CASGoogle Scholar
35 Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E: Klinefelter’s syndrome. Lancet364,273–283 (2004).
Medline CASGoogle Scholar
36 Ross JL, Roeltgen DP, Stefanatos G et al.: Cognitive and motor development during childhood in boys with Klinefelter syndrome. Am. J. Med. Genet.146A(6),708–719 (2008).
MedlineGoogle Scholar
37 Bruining H, Swaab H, Kas M, van Engeland H: Psychiatric characteristics in a self-selected sample of boys with Klinefelter syndrome. Pediatrics123(5),e865–e870 (2009).
MedlineGoogle Scholar
38 Lindstedt G, Nyström E, Matthews C, Ernest I, Janson PO, Chatterjee K: Follitropin (FSH) deficiency in an infertile male due to FSHb gene mutation. A syndrome of normal puberty and virilization but underdeveloped testicles with azoospermia, low FSH but high lutropin and normal serum testosterone concentrations. Clin. Chem. Lab. Med.36(8),663–665 (1998).
Medline CASGoogle Scholar
39 Weiss J, Axelrod L, Whitcomb RW, Harris PE, Crowley WF, Jameson JL: Hypogonadism caused by a single amino acid substitution in the β subunit of luteinizing hormone. N. Engl. J. Med.326(3),179–178 (1992).
Medline CASGoogle Scholar
40 Perniola R, Falorni A, Clemente MG, Forini F, Accogli E, Lobreglio G: Organ-specific and non-organ-specific autoantibodies in children and young adults with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Eur. J. Endocrinol.143(4),497–503 (2000).
Medline CASGoogle Scholar
41 Sinisi AA, D’Apuzzo A, Pasquali D, Venditto T et al.: Antisperm antibodies in prepubertal boys treated with chemotherapy for malignant or non-malignant diseases and in boys with genital tract abnormalities. Int. J. Androl.20(1),23–28 (1997).
Medline CASGoogle Scholar
42 Webb EA, Dattani MT: Septo-optic dysplasia. Eur. J. Hum. Genet.18(4),393–397, (2010)
MedlineGoogle Scholar
43 Sedlmeyer IL, Palmert MR: Delayed puberty: analysis of a large case series from an academic center. J. Clin. Endocrinol. Metab.87,1613–1620 (2002).
Medline CASGoogle Scholar
44 Palmert MR, Boepple PA: Variation in the timing of puberty: clinical spectrum and genetic investigation. J. Clin. Endocrinol. Metab.86,2364–2368 (2001).
Medline CASGoogle Scholar
45 Ghai K, Cara JF, Rosenfield RL: Gonadotropin releasing hormone agonist (nafarelin) test to differentiate gonadotropin deficiency from constitutionally delayed puberty in teen-age boys - a clinical research center study. J. Clin. Endocrinol. Metab.80(10),2980–2986 (1995)
Medline CASGoogle Scholar
46 Partsch CJ, Hermanussen M, Sippell WG: Differentiation of male hypogonadotropic hypogonadism and constitutional delay of puberty by pulsatile administration of gonadotropin-releasing hormone. J. Clin. Endocrinol. Metab.60,1196–1203 (1985)
Medline CASGoogle Scholar
47 Wilson DA, Hofman PL, Miles HL, Unwin KE, McGrail CE, Cutfield WS: Evaluation of the buserelin stimulation test in diagnosing gonadotropin deficiency in males with delayed puberty. J. Pediatr.148(1),89–94 (2006).
Medline CASGoogle Scholar
48 Apter D: Ultrasensitive new immunoassays for gonadotropins in the evaluation of puberty: Curr. Opin. Pediatr.5(4),481–487 (1993).
Medline CASGoogle Scholar
49 Brito VN, Batista MC, Borges MF et al.: Diagnostic value of fluorometric assays in the evaluation of precocious puberty. J. Clin. Endocrinol. Metab.84,3539–3544 (1999).
Medline CASGoogle Scholar
50 Neely EK, Hintz RL, Wilson DM et al.: Normal ranges for immunochemiluminometric gonadotropin assays. J. Pediatr.127(1),40–46 (1995).
Medline CASGoogle Scholar
51 Resende EA, Lara BH, Reis JD, Ferreira BP, Pereira GA, Borges MF: Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children. J. Clin. Endocrinol. Metab.92(4),1424–1429 (2007).
Medline CASGoogle Scholar
52 Bourguignon JP, Vanderschueren-Lodeweyckx M, Wolter R et al.: and idiopathic delayed puberty: a longitudinal study in an attempt to diagnose gonadotropin deficiency before puberty: J. Clin. Endocrinol. Metab.54(4),733–744 (1982).
Medline CASGoogle Scholar
53 Berger K, Carvalho LRS, Brito VN et al.: Predictive value of gonadotropin measurements by fluorometric method after GnRH test in the diagnosis of hypogonadotropic hypogonadism (HH) at prepuberal age. Presented at: The Endocrine Society’s 85th Annual Meeting. PA, USA. Program & Abstract, 601–601.32 (2003)
Google Scholar
54 Kauschansky A, Dickerman Z, Phillip M, Weintrob N, Strich D: Use of GnRH agonist and human chorionic gonadotrophin tests for differentiating constitutional delayed puberty from gonadotrophin deficiency in boys. Clin. Endocrinol. (Oxf.)56,603–607 (2002).
Medline CASGoogle Scholar
55 Degros V, Cortet-Rudelli C, Soudan B, Dewailly D: The human chorionic gonadotropin test is more powerful than the gonadotropin-releasing hormone agonist test to discriminate male isolated hypogonadotropic hypogonadism from constitutional delayed puberty. Eur. J. Endocrinol.149,23–29 (2003).
Medline CASGoogle Scholar
56 Segal TY, Mehta A, Anazodo A, Hindmarsh PC, Dattani MT: Role of gonadotropin-releasing hormone and human chorionic gonadotropin stimulation tests in differentiating patients with hypogonadotropic hypogonadism from those with constitutional delay of growth and puberty. J. Clin. Endocrinol. Metab.94(3),780–785 (2009).
Medline CASGoogle Scholar
57 Marshall WA, Tanner JM: Variations in pattern of pubertal changes in girls. Arch. Dis. Child44,291–303 (1969)
Medline CASGoogle Scholar
58 Marshall WA, Tanner JM: Variations in the pattern of pubertal changes in boys. Arch. Dis. Child45,13–23 (1970).
Medline CASGoogle Scholar
59 Goji K, Tanikaze S: Comparison between spontaneous gonadotropin concentration profiles and gonadotropin response to low-dose gonadotropin-releasing hormone in prepubertal and early pubertal boys and patients with hypogonadotropic hypogonadism: assessment by using ultrasensitive, time-resolved immunofluorometric assay. Pediatr. Res.31(5),535–539 (1992).
Medline CASGoogle Scholar
60 Partsch CJ, Hermanussen M, Sippell WG: Differentiation of male hypogonadotropic hypogonadism and constitutional delay of puberty by pulsatile administration of gonadotropin-releasing hormone. J. Clin. Endocrinol. Metab.60,1196–1203 (1985).
Medline CASGoogle Scholar
61 Zevenhuijzen H, Kelnar CJ, Crofton PM: Diagnostic utility of a low-dose gonadotropin-releasing hormone test in the context of puberty disorders Horm. Res.62(4),168–176 (2004).
Medline CASGoogle Scholar
62 Mainieri AS, Elnecave RH: Usefulness of the free α-subunit to diagnose hypogonadotropic hypogonadism. Clin. Endocrinol. (Oxf.)9(3),307–313 (2003).
Google Scholar
63 Wilson DA, Hofman PL, Miles HL, Unwin KE, McGrail CE, Cutfield WS: Evaluation of the buserelin stimulation test in diagnosing gonadotropin deficiency in males with delayed puberty. J. Pediatr.148(1),89–94 (2006).
Medline CASGoogle Scholar
64 Han TS, Bouloux PM: What is the optimal therapy for young males with hypogonadotrophic hypogonadism? Clin. Endocrinol. (Oxf.)72(6),731–737 (2010).
Medline CASGoogle Scholar
65 Mendonca BB, Domenice S, Arnhold IJ, Costa EM: 46,XY disorders of sex development (DSD). Clin. Endocrinol. (Oxf.)70(2),173–187 (2009).
Medline CASGoogle Scholar
66 Thorsson AV, Christiansen P, Ritzén M: Efficacy and safety of hormonal treatment of cryptorchidism: current state of the art. Acta. Paediatrica.96,628–630 (2007).
MedlineGoogle Scholar
67 Ritzén EM, Bergh A, Bjerknes R, Christiansen P et al.: Nordic consensus on treatment of undescended testes. Acta Paediatrica96,638–643 (2007).
MedlineGoogle Scholar
68 Shulman DI, Francis GL, Palmert MR, Eugster EA; Lawson Wilkins Pediatric Endocrine Society Drug and Therapeutics Committee: Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. Pediatrics121(4),975–983 (2008).
Google Scholar
69 Raivio T, Wikström AM, Dunkel L: Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome. Eur. J. Endocrinol.156,105–111 (2007).
Medline CASGoogle Scholar
70 Bougnères P, François M, Pantalone L et al.: Effects of an early postnatal treatment of hypogonadotropic hypogonadism with a continuous subcutaneous infusion of recombinant follicle-stimulating hormone and luteinizing hormone. J. Clin. Endocrinol. Metab.93,2202–2205 (2008).
Medline CASGoogle Scholar
71 Main KM, Schmidt IM, Toppari J, Skakkebaek NE: Early postnatal treatment of hypogonadotropic hypogonadism with recombinant human FSH and LH. Eur. J. Endocrinol.146(1),75–79 (2002).
Medline CASGoogle Scholar
72 Paduch DA, Bolyakov A, Cohen P, Travis A: Reproduction in men with Klinefelter syndrome: the past, the present, and the future. Semin. Reprod. Med.27(2),137–148 (2009).
MedlineGoogle Scholar
73 Jayasena CN, Dhillo WS: Kisspeptin offers a novel therapeutic target in reproduction. Curr. Opin. Investig. Drugs10(4),311–318 (2009).
Medline CASGoogle Scholar
74 Plant TM, Ramaswamy S, Di Pietro M: Repetitive activation of hypothalamic G protein-coupled receptor 54 with intravenous pulses of kisspeptin in the juvenile monkey (Macaca mulatta) elicits a sustained train of gonadotropin-releasing hormone discharges. Endocrinology147,1007–1013 (2006).
Medline CASGoogle Scholar
75 Seminara SB, Dipietro MJ, Ramaswamy S, Crowley WF Jr, Plant TM: Continuous human metastin 45–54 infusion desensitizes G protein-coupled receptor 54-induced gonadotropin-releasing hormone release monitored indirectly in the juvenile male Rhesus monkey (Macaca mulatta): a finding with therapeutic implications. Endocrinology147(5),2122–2126 (2006).
Medline CASGoogle Scholar
76 Patterson M, Murphy KG, Thompson EL, Patel S, Ghatei MA, Bloom SR: Administration of kisspeptin-54 into discrete regions of the hypothalamus potently increases plasma luteinising hormone and testosterone in male adult rats. J. Neuroendocrinol.18(5),349–354 (2006).
Medline CASGoogle Scholar
101 Centers for Disease Control and Prevention www.cdc.gov/growthchartscity
Google Scholar

Vol. 4, No. 5

Metrics

Downloaded 359 times

History

Published online 2 November 2010

Published in print October 2010

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

Male hypogonadism: childhood diagnosis and future therapies

Abstract

Bibliography